Leash Bio
Ian Quigley, PhD is the Co-Founder and CEO of Leash Bio, a new and scalable company. Prior to this role, Ian was a Senior Data Scientist at Recursion Pharmaceuticals, where he accelerated drug discovery using computer vision and robotics. He also worked as a Postdoctoral Researcher at the Salk Institute for Biological Studies, bringing a classical embryological model into the genomic age. Ian's experience also includes working as a Scientist at Arima Genomics, Inc. Ian holds a Ph.D in Molecular Genetics from The University of Texas at Austin and a BA in Biology and English from Rice University.
This person is not in any teams
Leash Bio
Every single machine learning (ML)-driven breakthrough, from language translation to Go championships, was immediately preceded not by an algorithmic innovation but by a massive, well-controlled, purpose-built dataset. An ML-driven breakthrough in medicinal chemistry is going to require a similar dataset, but such high-quality, well-structured experimental data doesn’t exist yet. We're building that data set by making physical measurements of lots of targets (with automated in-house protein production) screened against lots of compounds (with DNA-encoded chemical libraries). We're also building the ML models, that will eventually be generalizable across any protein and novel medicines using insights from our models.